Pathogenesis, diagnosis and therapeutic possibilities of esophageal cancer

Current Opinion in Gastroenterology

Volumn 23, Issue 4, 2007, Pages 456-461

  Siersema, Peter D ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Chemoradiotherapy; Esophageal cancer; Neoadjuvant; Staging; Stents

Indexed keywords

CISPLATIN; EPIRUBICIN; FLUORODEOXYGLUCOSE F 18; FLUOROURACIL;

CANCER CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CLINICAL TRIAL; DYSPHAGIA; ESOPHAGEAL ADENOCARCINOMA; GENE EXPRESSION; HUMAN; LYMPHADENECTOMY; MULTIPLE CYCLE TREATMENT; PATHOGENESIS; POSITRON EMISSION TOMOGRAPHY; REVIEW; STENT;

ESOPHAGEAL NEOPLASMS; ESOPHAGECTOMY; ESOPHAGOSCOPY; HUMANS; NEOADJUVANT THERAPY; NEOPLASM STAGING; PALLIATIVE CARE; POSITRON-EMISSION TOMOGRAPHY; ULTRASONOGRAPHY;

EID: 34249930189     PISSN: 02671379     EISSN: None     Source Type: Journal    
DOI: 10.1097/MOG.0b013e32816a91de     Document Type: Review

References (20)

1. Hao Y, Triadafilopoulos G, Sahbaie P, et al. Gene expression profiling reveals stromal genes expressed in common between Barrett's esophagus and adenocarcinoma. Gastroenterology 2006; 131:925-933. Important study using DNA microarray technology and revealing many candidate genes not previously identified in Barrett esophagus and esophageal adenocarcinoma.
2. de Jonge PJF, Steyerberg EW, Kuipers EJ, et al. Risk factors for the development of esophageal adenocarcinoma in Barrett's esophagus. Am J Gastroenterol 2006; 101:1421-1429.
3. Bowrey DJ, Griffin SM, Wayman J, et al. Use of alarm symptoms to select dyspeptics for endoscopy causes patients with curable esophagogastric cancer to be overlooked. Surg Endosc 2006; 20:1725-1728. Study showing that alarm symptoms to select patients for endoscopy identifies patients with esophagogastric cancers, however, often at an advanced and incurable stage, and therefore disputes the UK guideline recommending this policy.
4. van Vliet EP, Eijkemans MJ, Kuipers EJ, et al. A comparison between low-volume referring regional centers and a high-volume referral center in quality of preoperative metastasis detection in esophageal carcinoma. Am J Gastroenterol 2006; 101:234-242. Dutch study showing that, in assessing the operability of esophageal cancer, the diagnostic sensitivity of metastasis detection in a high-volume referral center was higher than in referring regional centers.
5. Vazquez-Sequeiros E, Levy MJ, Clain JE, et al. Routine vs. selective EUS-guided FNA approach for preoperative nodal staging of esophageal carcinoma. Gastrointest Endosc 2006; 63:204-211.
6. Ribeiro A, Franceschi D, Parra J, et al. Endoscopic ultrasound restaging after neoadjuvant chemotherapy in esophageal cancer. Am J Gastroenterol 2006; 101:1216-1221.
7. Ott K, Weber WA, Lordick F, et al. Metabolic imaging predicts response, survival, and recurrence in edenocarcinomas of the esophagogastric junction. J Clin Oncol 2006; 24:4692-4698. Study demonstrating that changes in tumor metabolic activity during chemotherapy predict response, prognosis and recurrence in patients with adenocarcinoma of the esophagogastric junction.
8. Malthaner RA, Collin S, Fenlon D. Preoperative chemotherapy for resectable thoracic esophageal cancer. Cochrane Database Syst Rev 2006; (3):CD001556.
9. Cunningham D, Allum WH, Stenning SP, et al. Perioperative chemotherapy versus surgery alone for respectable gastroesophageal cancer. N Engl J Med 2006; 355:11-20. Milestone study showing that in patients with operable lower esophageal or gastric adenocarcinomas, a preoperative regimen of epirubicin, cisplatin and fluorocuracil is able to improve overall survival.
10. Peters FP, Kara MA, Rosmolen WD, et al. Stepwise radical endoscopic resection is effective for complete removal of Barrett's esophagus with early neoplasia: a prospective study. Am J Gastroenterol 2006; 101:1449-1457.
11. Adams R, Morgan M, Mukherjee S, et al. A prospective comparison of multidisciplinary treatment of oesophageal cancer with curative intent in a UK cancer network. Eur J Surg Oncol 2006; 21 November [Epub ahead of print]. Study from the UK showing the importance of amultidisciplinary team in selecting the most optimal therapy for an individual patient with esophageal cancer. This study also shows that for patients deemed unfit for surgery, definitive chemoradiotherapy is a viable alternative.
12. Steyerberg EW, Neville BA, Koppert LB, et al. Surgical mortality in patients with esophageal cancer: development and validation of a simple risk score. J Clin Oncol 2006; 24:4277-4284. These authors developed a simple risk score, which combined clinical characteristics with hospital volume to predict surgical mortality after esophagectomy.
13. Rizk N, Venkatraman E, Park B, et al. The prognostic importance of the number of involved lymph nodes in esophageal cancer: implications for revisions of the American Joint Committee on Cancer staging system. J Thorac Cardiovasc Surg 2006; 132:1374-1381. Important clinical study showing that the current AJCC staging system needs revision in that the number of involved lymph nodes and minimal requirements for extent of lymphadenectomy should be included.
14. van Vliet EP, Eijkemans MJ, Steyerberg EW, et al. The role of socio-economic status in the decision making on diagnosis and treatment of esophageal cancer in The Netherlands. Br J Cancer 2006; 95:1180-1185. Study from the Netherlands showing that even when access to healthcare is similar for everyone, both patient and doctor determinants contribute to the decision on the most optimal treatment modality in patients with esophageal cancer.
15. Leigh Y, Seagroatt V, Goldacre M, et al. Impact of socio-economic deprivation on death rates after surgery for upper gastrointestinal tract cancer. Br J Cancer 2006; 95:940-943.
16. Homs MY, van der Gaast A, Siersema PD, et al. Chemotherapy for metastatic carcinoma of the esophagus and gastro-esophageal junction. Cochrane Database Syst Rev 2006, (4): CD004063.
17. Herskovic A, Martz K, Al-Sarraf M, et al. Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus. N Eng J Med 1992; 326:1593-1598.
18. Verschuur EM, Homs MY, Steyerberg EW, et al. A new esophageal stent design (Niti-S stent) for the prevention of migration: a prospective study in 42 patients. Gastrointest Endosc 2006; 63:134-140.
19. Lecleire S, Di Fiore F, Antonietti M. Undernutrition is predictive of early mortality after palliative self-expanding metal stent insertion in patients with inoperable or recurrent esophageal cancer. Gastrointest Endosc 2006; 64:479-484.
20. Ross WA, Alkassab F, Lynch PM. Evolving role of self-expanding metal stents in the treatment of malignant dysphagia and fistulas. Gastrointest Endosc 2007; 65:70-76. Provocative study from MD Anderson, Houston, Texas (USA) concluding that stents fall short of an ideal palliative method in patients with esophageal cancer and claiming that patients should be treated with chemoradiation.